Lepu Healthcare made a net profit of $1.2 billion from strong sales of bio-absorbable stents

first half of 2019, Lepu Healthcare's net profit increased by 40%-50%, and sales of bio-absorbable stents were strong.Half-yearly resultsOn the evening of July 10th, Lepu Healthcare released its 2019 half-year results, forecasting net profit of between $1.13 billion and $1.21 billion, up 40%-50% from the same period last year.
Cypress Blue Device Statistics: As of July 11, a total of 7 listed medical device companies issued a half-year results report, only Jianfan Bio's net profit growth rate and Lepu Medical equivalent, between 35% and 55%, but the net profit is far lower than Lepu Medical, a maximum of about 330 million yuan.
has been growing at a high rate in recent years - with total revenue growth of 31 per cent and 40 per cent in 2017 and 2018, net profit growth of 32 per cent and 36 per cent, and gross margins of 67 per cent and 73 per cent, according to annual reports.
the reasons for the first-half 2019 results growth, Lepu Medical said in a statement that its newly developed NeoVas bio-absorbable support, or NeoVas, has been contributing strong new earnings growth since it went on sale in late March.10 years, on February 27 this year, Lepu Medical NeoVas finally obtained a medical device registration certificate approved by the State Drug Administration, according to public information on , a new source of profits.
According to Lepu Medical, NeoVas is the first approved bio-absorbent stent approved for sale in China, implanted in the human body, after blood transport reconstruction, stent degradation absorption and vascular repair three stages, and finally completely degraded, the structure and function of blood vessels were restored.
and NeoVas is in a huge market.
2018 Chinese mainland Coronary Heart Disease PCI data show that the total number of cases of coronary heart disease intervention in mainland China was 915,000, the average number of coronary heart disease patients implanted with stents was 1.46, a total of about 1.34 million

Despite the tightening of price controls in recent years, LeP Medical said that the approval of NeoVas' registration at least three years earlier than its main competitors would effectively withstand the impact of lower revenue from future annual collection or other product price cuts, which would lead to rapid growth over the next 3-5 years.
third-party research and analysis, NeoVas in the year of listing is the only biodegradable bracket on sale in China. Assuming that the degradable bracket terminal sells for 30,000 yuan per person, a single bracket contributes a profit of about 10,000 yuan. Based on the current annualized growth rate of surgical use, it is expected to contribute 1 billion yuan in profits by 2021.
the same time, Lep Medical's coronary drug balloon product is nearing completion of clinical trial follow-up and will complement NeoVas bio-absorbable stents.or the existence of multiplebut the market may not contribute directly to a smooth upward curve.
In fact, there were three technological revolutions in coronary stents prior to the ad-emergence of bio-absorbent stents, namely, the 1977 perceptial coronary angioformation, the 1988 metal bare stent, and the 2000 drug-washed stent.
Although there is media will be bio-absorbent stents as the 4th technological revolution, but Fudan University affiliated Zhongshan Hospital, deputy director of cardiovascular medicine, Shen Wei has said that bio-absorbable stents still need more clinical practice to verify, the current limitations are mainly in stent mechanical properties, stent enditerization speed, stent thrombosis, stent degradation speed and local inflammation, clinical lesions applicable range.
" where mechanical properties, bio-absorbable stents use bio-polymer polylactic acid (PLLA) as a support material, but poor scalability, low maximum pull strength, small elastic mods limit the ability to expand back. Mr Shen said.NeoVas' substation is made of left-handed polylactic acid (PLLA), according to Lepp Medical Bulletin.
addition, the age limit may also be a big short board for NeoVas.
, according to the website of the Henan Provincial People's Government, NeoVas was the first bio-absorbent stent implant in Henan province to be successfully performed this year, and the patient who underwent the procedure was only 30 years old.
experts say the new stent is usually suitable for heart patients under 60 years of age, and is most suitable for simple lesions, such as poor vascular elasticity, calcification lesions, etc.
But according to China Industry Information Network data, from the age distribution of patients undergoing coronary interventional surgery, more than 60% of patients in the United States are older than 60 years old, and the average age of Chinese patients is 62 years old - there is a degree of dissocence with the current population of such products.The exiting Abbott , speaking of NeoVas at Lep Healthcare, had to mention Abbott's world's first bioabsorb GT1 BVS.
July 2016, the FDA approved Abbott Absorb's listing, and just one year later, on September 8, 2017, Abbott announced that it was stopping selling Absorb worldwide.
explained to Abbott that Absorb stopped selling because sales were less than 1 per cent of all Abbott bracket sales and manufacturing costs were higher than sales costs.
the exit of Abbott's bioabsorb, which was in the research and development phase at the time, has attracted attention.
medical analysis, due to the clinical failure to strictly implement PSP operating norms, resulting in market misunderstanding of the safety of Absorb stents. And when it comes to deciding on a commercial exit, Absorb's clinical data for the recovery period are not available, and the results may be different when the data comes out.
but the market view is that Abbott's exit actually has more to watch out for. Before Absorb went on sale, U.S. government scientists questioned the potential risk of heart attack and blood clots in patients using the stent.
, in October 2016, six of the patients implanted with Absorb developed blood clots a year later, according to tctMD, and a follow-up study of 501 patients showed an increased risk of late stent thrombosis after Absorb was implanted.
May 2017, Australia issued a "danger alert" to Abbott Absorb, removing it from Australia's therapeutic products register and recalling any unused products that were not involved in clinical trials. (Saibo Blue Device)